CG Oncology/$CGON
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About CG Oncology
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Ticker
$CGON
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
113
Website
CG Oncology Metrics
BasicAdvanced
$2B
-
-$1.51
-
-
Price and volume
Market cap
$2B
52-week high
$39.50
52-week low
$14.80
Average daily volume
939K
Financial strength
Current ratio
30.969
Quick ratio
30.42
Long term debt to equity
0.111
Total debt to equity
0.147
Profitability
EBITDA (TTM)
-134.349
Gross margin (TTM)
-13,851.51%
Net profit margin (TTM)
-15,945.17%
Operating margin (TTM)
-20,302.27%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-12.85%
Return on equity (TTM)
-16.57%
Valuation
Price to revenue (TTM)
2,813.323
Price to book
2.89
Price to tangible book (TTM)
2.89
Price to free cash flow (TTM)
-22.652
Free cash flow yield (TTM)
-4.41%
Free cash flow per share (TTM)
-1.178
Growth
Revenue change (TTM)
22.82%
Earnings per share change (TTM)
-68.35%
What the Analysts think about CG Oncology
Analyst ratings (Buy, Hold, Sell) for CG Oncology stock.
Bulls say / Bears say
CG Oncology's successful IPO in January 2024 raised $380 million, providing substantial capital to advance its clinical programs. (money.usnews.com)
The company's Phase 3 BOND-003 trial results for cretostimogene monotherapy in BCG-unresponsive NMIBC were accepted as a late-breaking abstract at the SUO 25th Annual Meeting, indicating promising clinical progress. (stocktitan.net)
Analysts from HC Wainwright have reiterated a 'Buy' rating for CG Oncology, reflecting confidence in the company's growth prospects. (etfdailynews.com)
CG Oncology reported a net loss of $20.4 million in Q3 2024, with increased R&D and G&A expenses, raising concerns about its financial sustainability. (stocktitan.net)
The company's stock price experienced a 9% decline following the announcement of a public offering in December 2024, indicating potential investor apprehension. (benzinga.com)
CG Oncology's share price has been volatile, with a 14% weekly volatility over the past year, which may deter risk-averse investors. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
CG Oncology Financial Performance
Revenues and expenses
CG Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for CG Oncology stock?
CG Oncology (CGON) has a market cap of $2B as of August 01, 2025.
What is the P/E ratio for CG Oncology stock?
The price to earnings (P/E) ratio for CG Oncology (CGON) stock is 0 as of August 01, 2025.
Does CG Oncology stock pay dividends?
No, CG Oncology (CGON) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next CG Oncology dividend payment date?
CG Oncology (CGON) stock does not pay dividends to its shareholders.
What is the beta indicator for CG Oncology?
CG Oncology (CGON) does not currently have a Beta indicator.